Published in Front Chem on November 27, 2014
Silver nanoparticle protein corona and toxicity: a mini-review. J Nanobiotechnology (2015) 0.84
An antigen-encapsulating nanoparticle platform for TH1/17 immune tolerance therapy. Nanomedicine (2016) 0.78
Differential Impact of Plasma Proteins on the Adhesion Efficiency of Vascular-Targeted Carriers (VTCs) in Blood of Common Laboratory Animals. Bioconjug Chem (2015) 0.77
Preparation of Core-Shell Hybrid Materials by Producing a Protein Corona Around Magnetic Nanoparticles. Nanoscale Res Lett (2015) 0.77
Probing the Interaction between Nanoparticles and Lipid Membranes by Quartz Crystal Microbalance with Dissipation Monitoring. Front Chem (2016) 0.75
Effect of anticoagulants on the protein corona-induced reduced drug carrier adhesion efficiency in human blood flows. Acta Biomater (2016) 0.75
Surface plasmon resonance as a high throughput method to evaluate specific and non-specific binding of nanotherapeutics. J Control Release (2015) 0.75
Tweaking dendrimers and dendritic nanoparticles for controlled nano-bio interactions: potential nanocarriers for improved cancer targeting. J Drug Target (2015) 0.75
Charged group surface accessibility determines micelleplexes formation and cellular interaction. Nanoscale (2015) 0.75
Synthesis, characterization and radiolabeling of polymeric nano-micelles as a platform for tumor delivering. Biomed Pharmacother (2017) 0.75
Technetium-99m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo. Biomed Pharmacother (2017) 0.75
IgA and IgM protein primarily drive plasma corona-induced adhesion reduction of PLGA nanoparticles in human blood flow. Bioeng Transl Med (2017) 0.75
The species origin of the serum in the culture medium influences the in vitro toxicity of silica nanoparticles to HepG2 cells. PLoS One (2017) 0.75
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater (2009) 11.95
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm (2005) 7.53
Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A (2007) 7.50
Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther (2007) 5.79
Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A (2008) 5.76
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol (2011) 4.22
Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol (2012) 3.48
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol (2013) 3.39
Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci U S A (2007) 3.23
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proc Natl Acad Sci U S A (2011) 2.66
Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc (2012) 2.55
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol (2013) 2.54
Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano (2014) 2.17
Sheddable coatings for long-circulating nanoparticles. Pharm Res (2007) 2.15
Detecting cryptic epitopes created by nanoparticles. Sci STKE (2006) 2.02
PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett (2012) 1.77
Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. J Nanobiotechnology (2013) 1.57
Strategies for advancing cancer nanomedicine. Nat Mater (2013) 1.48
Complete high-density lipoproteins in nanoparticle corona. FEBS J (2009) 1.47
Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. Nano Lett (2007) 1.37
Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard corona. ACS Nano (2012) 1.35
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev (2013) 1.29
Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. Blood (1980) 1.25
Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv (2011) 1.23
pH-dependent protein conformational changes in albumin:gold nanoparticle bioconjugates: a spectroscopic study. Langmuir (2007) 1.20
Silver nanoparticle protein corona composition in cell culture media. PLoS One (2013) 1.13
Protein corona composition of superparamagnetic iron oxide nanoparticles with various physico-chemical properties and coatings. Sci Rep (2014) 1.06
Protein corona significantly reduces active targeting yield. Chem Commun (Camb) (2013) 1.05
Translating materials design to the clinic. Nat Mater (2013) 1.03
Surface polyethylene glycol conformation influences the protein corona of polyethylene glycol-modified single-walled carbon nanotubes: potential implications on biological performance. ACS Nano (2013) 1.02
Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.02
Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. ACS Nano (2013) 1.02
Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials. ACS Nano (2014) 0.97
Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting. Angew Chem Int Ed Engl (2014) 0.96
The nano-plasma interface: Implications of the protein corona. Colloids Surf B Biointerfaces (2014) 0.90
Serum protein identification and quantification of the corona of 5, 15 and 80 nm gold nanoparticles. Nanotechnology (2013) 0.89
Secondary structure of corona proteins determines the cell surface receptors used by nanoparticles. J Phys Chem B (2014) 0.89
Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol (2003) 0.89
Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. Biomaterials (2013) 0.86
Dendritic nanoparticles: the next generation of nanocarriers? Ther Deliv (2012) 0.86
Shrinkage of pegylated and non-pegylated liposomes in serum. Colloids Surf B Biointerfaces (2013) 0.86
Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles. J Control Release (2014) 0.85
Formation and characterization of the nanoparticle-protein corona. Methods Mol Biol (2013) 0.84
Magnetic nanoparticles to recover cellular organelles and study the time resolved nanoparticle-cell interactome throughout uptake. Small (2014) 0.83
Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats. Nanoscale (2014) 0.83
Protein corona change the drug release profile of nanocarriers: the "overlooked" factor at the nanobio interface. Colloids Surf B Biointerfaces (2014) 0.82
Dynamic development of the protein corona on silica nanoparticles: composition and role in toxicity. Nanoscale (2013) 0.80
Influence of protein corona on the transport of molecules into cells by mesoporous silica nanoparticles. ACS Appl Mater Interfaces (2013) 0.78
Size and surface functionalization of iron oxide nanoparticles influence the composition and dynamic nature of their protein corona. ACS Appl Mater Interfaces (2014) 0.76